StockData
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP) stock

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.87−0.03 (-0.77%)

Close on Nov 17, 2026Market cap $160.98MP/E 0.9Yield 6.46%

Oramed Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Oramed Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$14.52M. For fiscal 2025 it was -$15.09M. The highest annual figure on record is $4.30M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$15.09M–
FY2024Dec 31, 2024-$12.78M–
FY2023Dec 31, 2023-$15.77M–
FY2021Aug 31, 2021-$24.22M–
FY2020Aug 31, 2020-$11.76M–
FY2019Aug 31, 2019-$14.63M–
FY2018Aug 31, 2018-$13.53M–
FY2017Aug 31, 2017-$10.77M–
FY2016Aug 31, 2016-$10.01M–
FY2015Aug 31, 2015-$7.38M–
FY2014Aug 31, 2014-$5.91M-237.2%
FY2013Aug 31, 2013$4.30M–
FY2012Aug 31, 2012-$2.88M–
FY2011Aug 31, 2011-$2.44M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$2.77M–
Q1 FY2026CQ1 2026Mar 31, 2026-$3.66M–
Q4 FY2025CQ4 2025Dec 31, 2025-$5.67M–
Q3 FY2025CQ3 2025Sep 30, 2025-$2.43M–
Q2 FY2025CQ2 2025Jun 30, 2025-$2.49M–
Q1 FY2025CQ1 2025Mar 31, 2025-$4.50M–
Q4 FY2024CQ4 2024Dec 31, 2024-$3.60M–
Q3 FY2024CQ3 2024Sep 30, 2024-$3.09M–
Q2 FY2024CQ2 2024Jun 30, 2024-$3.14M–
Q1 FY2024CQ1 2024Mar 31, 2024-$2.96M–
Q4 FY2023CQ4 2023Dec 31, 2023-$3.88M–
Q3 FY2023CQ3 2023Sep 30, 2023-$2.89M–
Q2 FY2023CQ2 2023Jun 30, 2023-$3.79M–
Q1 FY2023CQ1 2023Mar 31, 2023-$5.21M–
Q4 FY2021CQ3 2021Aug 31, 2021-$7.41M–
Q3 FY2021CQ2 2021May 31, 2021-$6.12M–
Q2 FY2021CQ1 2021Feb 28, 2021-$4.87M–
Q1 FY2021CQ4 2020Nov 30, 2020-$5.83M–
Q4 FY2020CQ3 2020Aug 31, 2020-$3.02M–
Q3 FY2020CQ2 2020May 31, 2020-$2.27M–
Q2 FY2020CQ1 2020Feb 29, 2020-$4.04M–
Q1 FY2020CQ4 2019Nov 30, 2019-$2.43M–
Q4 FY2019CQ3 2019Aug 31, 2019-$2.35M–
Q3 FY2019CQ2 2019May 31, 2019-$4.08M–
Q4 FY2018CQ3 2018Aug 31, 2018-$3.15M–
Q3 FY2018CQ2 2018May 31, 2018-$4.53M–
Q2 FY2018CQ1 2018Feb 28, 2018-$3.11M–
Q1 FY2018CQ4 2017Nov 30, 2017-$2.73M–
Q4 FY2017CQ3 2017Aug 31, 2017-$2.85M–
Q3 FY2017CQ2 2017May 31, 2017-$2.16M-202.1%
Q2 FY2017CQ1 2017Feb 28, 2017-$3.37M–
Q1 FY2017CQ4 2016Nov 30, 2016-$2.40M-197.9%
Q4 FY2016CQ3 2016Aug 31, 2016-$16.48M–
Q3 FY2016CQ2 2016May 31, 2016$2.11M–
Q2 FY2016CQ1 2016Feb 29, 2016-$1.91M–
Q1 FY2016CQ4 2015Nov 30, 2015$2.45M–
Q4 FY2015CQ3 2015Aug 31, 2015-$2.17M–
Q3 FY2015CQ2 2015May 31, 2015-$1.63M–
Q2 FY2015CQ1 2015Feb 28, 2015-$1.67M–

More Oramed Pharmaceuticals figures

See a number that looks wrong?